clinical study retractions – Page 9

Drug company withdraws court motion requesting retraction of papers critical of its painkiller

A drug maker has blinked in a lawsuit against the leading anesthesiology society in the United States, along with several anesthesiology researchers, who it claims libeled the company in a series of articles and other materials critical of its main product.

As we reported last month, Pacira Biosciences, which makes the local anesthetic agent Exparel, field the suit in federal court in April, alleging that the American Society of Anesthesiologists (ASA), the editor of its flagship journal, Anesthesiology, and others, were unfairly targeting the drug.

The company asked the court for a preliminary injunction to retract two papers and an editorial about Exparel that Anesthesiology published in February. But on May 7, Pacira withdrew the motion, about a week after the ASA filed its own motion calling for a quick hearing on the merits of the company’s motion.

According to an unusually forceful statement (for a medical society) from the ASA:

“Yep, pretty slow”: Nutrition researchers lose six papers

Six months after we reported that journals had slapped expressions of concern on more than three dozen papers by a group of nutrition researchers in Iran, the retractions have started to trickle in.

But clock started nearly two years ago, after data sleuths presented journals with questions about the findings in roughly 170 papers by the authors. So far we’ve seen only six retractions, from two journals, of the suspect papers. As one of the sleuths said, “yep, pretty slow.”

Central to the case is Zatollah Asemi, of the Department of Nutrition at Kashan University of Medical Sciences. As we wrote last November:

“We didn’t want to hurt them. We are polite”: When a retraction notice pulls punches

A group of anesthesiology researchers in China have lost their 2020 paper on nerve blocks during lung surgery after finding that the work contained “too many” errors to stand. But after hearing from the top editor of the journal, it’s pretty clear “too many errors” was a euphemism for even worse problems.

The article, “Opioid-sparing effect of modified intercostal nerve block during single-port thoracoscopic lobectomy: A randomised controlled trial,” came from a team at Anhui Medical University. The senior author was Guang-hong Xu. The paper appeared online in early December in the European Journal of Anaesthesiology.

At which point it caught the attention of a reader in Australia, who emailed the journal to point out fishiness in the data.

Charles Marc Samama, the editor-in-chief of the EJA, told us:

Clinical trial paper that made anemia drug look safer than it is will be retracted

A study that a pharmaceutical company admitted last month included manipulated data will be retracted, Retraction Watch has learned.

The paper, “Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis,” was published in Kidney International Reports in December 2020. The study analyzed data from a clinical trial for roxadustat, a drug intended to help anemic patients make more red blood cells. The medicine was tested in more than 1,500 patients with kidney failure that had been on dialysis for less than four months.

The paper compared roxadustat to a standard treatment, epoetin alfa. Epoetin alfa is not given to anemic patients who have kidney disease and are not dependent on dialysis, according to reporting in April by FiercePharma, because it can increase the risk of a cardiovascular event, including heart attacks.

In the study, roxadustat was as effective as epoetin alfa for these patients, but carried a 30 percent lower risk for death, heart attacks or strokes.

Then, on April 6th, Fibrogen announced, according to FiercePharma, that researchers had

Journal retracts paper by ‘miracle doctor’ claiming life force kills cancer cells

A “miracle doctor” in China and his colleagues have lost a 2007 paper on the ability of the martial art qigong to treat cancer after the journal that published the work said it failed to properly vet the findings.

Well, the first part of that is true. The second part is implied. We’ll explain.

The paper, “External Qi of Yan Xin Qigong induces G2/M arrest and apoptosis of androgen-independent prostate cancer cells by inhibiting Akt and NF-B pathways,” appeared in December 2007 in Molecular and Cellular Biochemistry, a Springer Nature journal. It has been cited 20 times, according to Clarivate Analytics’ Web of Science.

The first author on the study was Yan Xin, whose biography states that he is a “miracle doctor” and one of the world’s experts in the healing properties of qi — the universal life force in traditional Chinese medicine and philosophy. His co-authors include researchers at Harvard, McMaster University in Canada, and the New Medical Science Research Institute in New York City.

‘Unfair and unsubstantiated’: Journal retracts paper suggesting smoking is linked to lower COVID-19 risk

A paper suggesting that smokers were significantly less likely than nonsmokers to contract Covid-19 has been retracted because the authors failed to disclose financial ties to … the tobacco industry.

The article, which appeared as a preprint and then as an “early view” in the European Respiratory Journal last July, came from a group at the University of Piraeus, in Greece, and the University of Utah. The first author was Theodoros Giannouchos, currently a post-doc at the University of Utah, and the senior author was Konstantinos Farsalinos, a fairly prominent name in the world of vaping research.

Some vaping advocates have pointed to a protective effect of nicotine against Covid-19. According to the preprint of the now-retracted paper:

Palmitoleic acid paper pulled for data concerns

A journal has retracted the 2014 report of a clinical trial of a supplement touted as a way to reduce the risk of cardiovascular disease after beginning to suspect that the data were not reliable.

The study, “Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled study,” was published in the Journal of Clinical Lipidology, an Elsevier title. It has been cited 42 times, according to Clarivate Analytics’ Web of Science.

The authors were Adam Bernstein and Michael Roizen, of the Wellness Institute at Cleveland Clinic, and Luis Martinez, who at the time was the president of the Xyrion Medical Institute, in Puerto Rico.

Roizen, an anesthesiologist and the founding chair of the Wellness Institute, is the co-creator of the RealAge test, which he developed along with Mehmet Oz.

Roizen and Oz have been hawking palmitoleic acid — an omega-7 fatty acid that is the subject of the now-retracted study — for some time. In this 2019 article, for example, the pair wrote:

A longtime whistleblower explains why he’s spent more than a decade trying to get a paper retracted

Since the report of the MIST Trial was published in Circulation in 2008, I have repeatedly written to the journal to express concern about the paper.

Most recently, on February 22, I wrote to the editor-in-chief of Circulation, which is owned by the American Heart Association (AHA), requesting that they retract the 2008 MIST Trial paper, the revised version of the paper, the correction and the data supplement. The response two days later was from the senior attorney of the AHA: “AHA respectfully declines any further involvement. We consider this matter closed and we will not pursue additional comment or review.”

Let me explain how I got involved, and why I have persisted. I was the principal cardiologist in the MIST Trial sponsored by NMT Medical. Another member of the steering committee (Simon Nightingale) and I refused to be authors of the paper because NMT had refused to allow any investigator to see all the data but even without access to the data it was clear that the paper made false claims. In November 2007, a few days after we refused to be authors, NMT started legal proceedings for libel and slander against me. They also instructed their lawyers to sue Nightingale, but did not start the legal proceedings against him.

Paper claiming Muslim patients are “particularly sensitive” retracted

A paper about medical treatment for migrant patients in Germany has been retracted after the authors made unsupported claims that Muslims are “particularly sensitive” to pain.

The paper, titled “Diversität im klinischen Alltag der Augenheilkunde,” or “Diversity in everyday clinical practice in ophthalmology,” in English, was published in Der Ophthalmologe, a German medical journal, in November 2019. It has not yet been cited, according to Clarivate Analytics’ Web of Science.

The original article, penned by ophthalmologists at the Cologne University Eye Clinic, is in German. We ran it through Google Translate to get a sense of its content. The paper begins with a case study of a 52 year-old Turkish migrant, explains how to use smartphone speech translators to overcome language barriers, and highlights cultural differences that physicians should consider while treating migrants.

Former Cleveland Clinic researcher’s papers “more likely than not” included falsified images, says investigation

A former researcher at the Cleveland Clinic who studied cardiac genetics has lost three papers for what an institutional investigation concluded was “more likely than not” a case image falsification.

As we reported last year, the work of Subha Sen, once a highly funded scientist at Cleveland Clinic but who left the institution in 2011, has come under scrutiny on PubPeer (note: a researcher with the same name, but at a different institution, also appears in these search results). With the latest papers, Sen now has ~~nine~~ seven retractions for issues including questions about the integrity of the data and the validity of the images.

The three newest removals involve studies published in the American Journal of Physiology-Heart and Circulatory Physiology between 2004 and 2009. The notices are very similar while referring to different images.

Here’s the statement for the 2005 article, “Inhibition of NF-κB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats”:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this: